title: Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
abstract: BACKGROUND
  Studies have suggested that the 5-year survival of women with ovarian cancer and a BRCA1 or BRCA2 mutation is better than expected. We sought to evaluate the impact of carrying a BRCA1 or BRCA2 mutation on long-term survival of women after a diagnosis of invasive ovarian cancer.
  
  
  METHODS
  One thousand six hundred twenty-six unselected women diagnosed with invasive ovarian cancer in Ontario, Canada, or in Tampa, Florida, between 1995 and 2004 were followed for a mean of 6.9 years (range = 0.3 to 15.7 years). Mutation screening for BRCA1 and BRCA2 revealed mutations in 218 women (13.4%). Left-truncated survival analysis was conducted to estimate ovarian cancer-specific survival at various time points after diagnosis for women with and without mutations.
  
  
  RESULTS
  In the 3-year period after diagnosis, the presence of a BRCA1 or BRCA2 mutation was associated with a better prognosis (adjusted hazard ratio = 0.68, 95% confidence interval [CI] = 0.48 to 0.98; P = .03), but at 10 years after diagnosis, the hazard ratio was 1.00 (95% CI = 0.83 to 1.22; P = .90). Among women with serous ovarian cancers, 27.4% of women who were BRCA1 mutation carriers, 27.7% of women who were BRCA2 carriers, and 27.1% of women who were noncarriers were alive at 12 years past diagnosis.
  
  
  CONCLUSIONS
  For women with invasive ovarian cancer, the short-term survival advantage of carrying a BRCA1 or BRCA2 mutation does not lead to a long-term survival benefit.
authors.affiliation: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada.
authors.forename: John R
authors.initials: JR
authors.lastname: McLaughlin
authors.forename: Barry
authors.initials: B
authors.lastname: Rosen
authors.forename: Joel
authors.initials: J
authors.lastname: Moody
authors.forename: Tuya
authors.initials: T
authors.lastname: Pal
authors.forename: Isabel
authors.initials: I
authors.lastname: Fan
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Shaw
authors.forename: Harvey A
authors.initials: HA
authors.lastname: Risch
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Sellers
authors.forename: Ping
authors.initials: P
authors.lastname: Sun
authors.forename: Steven A
authors.initials: SA
authors.lastname: Narod
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D005260:Female; D005431:Florida / Q000453:epidemiology; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009154:Mutation; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016017:Odds Ratio; D009864:Ontario / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D012042:Registries; D013997:Time Factors